Leading contract diagnostics organization demonstrates the value of DNA-based testing for identifying the HER2-Low genomic subtype in high-risk HER2 equivocal breast cancer Irvine, CA—December 1, 2016—ResearchDx/PacificDx announced today that it will share findings demonstrating the value of DNA microarray comparative genomic hybridization (array CGH) for HER2 genomic subtyping in breast cancer patients at this year’s San […]